Gabriele Valentini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6153419/publications.pdf

Version: 2024-02-01

137 papers	12,113 citations	50276 46 h-index	26613 107 g-index
137 all docs	137 docs citations	137 times ranked	9585 citing authors

#	Article	IF	Citations
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.9	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
5	Systemic Sclerosis. Medicine (United States), 2002, 81, 139-153.	1.0	648
6	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
7	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the Rheumatic Diseases, 2012, 71, 1355-1360.	0.9	275
8	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. PLoS Genetics, 2011, 7, e1002091.	3.5	205
9	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
10	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, 2017, 76, 270-276.	0.9	132
11	Adult-onset Stillâ€™s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Medicine, 2016, 14, 194.	5.5	130
12	â€œTo Be or Not To Be,â€•Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Seminars in Arthritis and Rheumatism, 2012, 41, 589-598.	3.4	126
13	Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes and Vascular Disease Research, 2007, 4, 130-135.	2.0	120
14	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	5.8	107
15	Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. Journal of Rheumatology, 2003, 30, 1630-47.	2.0	104
16	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
17	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. Microvascular Research, 2013, 89, 122-128.	2.5	101
18	High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clinical Rheumatology, 2007, 26, 710-714.	2.2	96

#	Article	IF	Citations
19	Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. Journal of Rheumatology, 2002, 29, 731-6.	2.0	93
20	Echocardiographic alterations in systemic sclerosis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2005, 34, 721-727.	3.4	88
21	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Research and Therapy, 2014, 16, R144.	3.5	88
22	The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiology, 2005, 34, 35-41.	2.0	86
23	Adult-onset Stillâ€™s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	2.2	83
24	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.9	82
25	Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2017, 44, 1032-1038.	2.0	79
26	Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. Autoimmunity Reviews, 2014, 13, 1026-1034.	5.8	78
27	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
28	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
29	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
30	Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology, 2009, 48, 1414-1417.	1.9	74
31	Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart, 2011, 97, 112-117.	2.9	74
32	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. Journal of Rheumatology, 2018, 45, 864-872.	2.0	70
33	Prevalence of hepatitis C serum antibody in autoimmune diseases. Journal of Autoimmunity, 2009, 32, 261-266.	6.5	65
34	Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. Journal of Autoimmunity, 2012, 39, 112-116.	6.5	65
35	Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. European Journal of Endocrinology, 2003, 148, 383-388.	3.7	64
36	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis and Rheumatism, 2012, 64, 2746-2752.	6.7	63

#	Article	IF	Citations
37	The Role of Infections in the Immunopathogensis of Systemic Sclerosisâ€“Evidence from Serological Studies. Annals of the New York Academy of Sciences, 2009, 1173, 627-632.	3.8	61
38	Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology, 2011, 50, 317-323.	1.9	61
39	Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. Journal of Clinical Immunology, 2014, 34, 663-668.	3.8	61
40	Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. Journal of Clinical Immunology, 2001, 21, 210-217.	3.8	60
41	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	1.9	60
42	Foot involvement in systemic sclerosis: A longitudinal study of 100 patients. Seminars in Arthritis and Rheumatism, 2002, 31, 248-255.	3.4	57
43	Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism: Clinical and Experimental, 1991, 40, 902-907.	3.4	56
44	Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Seminars in Arthritis and Rheumatism, 2015, 44, 437-444.	3.4	51
45	Stress Doppler Echocardiography in Systemic Sclerosis: Evidence for a Role in the Prediction of Pulmonary Hypertension. Arthritis and Rheumatism, 2013, 65, 2403-2411.	6.7	50
46	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
47	Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity. Arthritis Care and Research, 2014, 66, 1520-1527.	3.4	48
48	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Annals of the Rheumatic Diseases, 2016, 75, 1697-1705.	0.9	48
49	Pregnancy and systemic sclerosis. Arthritis and Rheumatism, 1985, 28, 237-238.	6.7	46
50	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Annals of the Rheumatic Diseases, 2006, 66, 249-252.	0.9	46
51	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. Journal of Rheumatology, 2009, 36, 1464-1469.	2.0	45
52	Increased Expression of CD40 Ligand in Activated CD4+T Lymphocytes of Systemic Sclerosis Patients. Journal of Autoimmunity, 2000, 15, 61-66.	6.5	44
53	A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256.	6.7	41
54	The origin of tendon friction rubs in patients with systemic sclerosis: A sonographic explanation. Arthritis and Rheumatism, 2012, 64, 1291-1293.	6.7	41

#	Article	IF	Citations
55	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
56	Systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2002, 16, 807-816.	3.3	39
57	Successful neridronate therapy in transient osteoporosis of the hip. Clinical Rheumatology, 2005, 24, 67-69.	2.2	39
58	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. Journal of Rheumatology, 2010, 37, 1852-1857.	2.0	39
59	High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. PLoS ONE, 2014, 9, e105008.	2.5	39
60	The assessment of the patient with systemic sclerosis. Autoimmunity Reviews, 2003, 2, 370-376.	5.8	38
61	Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Research and Therapy, 2013, 15, R63.	3.5	38
62	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 420-427.	0.9	37
63	â^'238 and +489 TNF-Î± along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunology Letters, 2005, 96, 103-108.	2.5	33
64	Cardiac Involvement in Rheumatoid Arthritis: An Echocardiographic Study. Cardiology, 1993, 83, 234-239.	1.4	32
65	Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Research and Therapy, 2012, 14, R188.	3.5	31
66	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. Autoimmunity Reviews, 2015, 14, 575-578.	5.8	31
67	Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as) Tj ETQq1 1 0.784314 rgBT /Overlo	5.8	31
68	Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology, 2016, 55, 1623-1630.	1.9	31
69	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.9	31
70	Proximal stomach function in systemic sclerosis: relationship with autonomic nerve function. Digestive Diseases and Sciences, 2001, 46, 723-730.	2.3	30
71	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 2011, 70, 1178-1182.	0.9	30
72	New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. Autoimmunity Reviews, 2015, 14, 812-829.	5.8	28

#	Article	IF	Citations
73	Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clinical and Experimental Immunology, 2006, 144, 169-176.	2.6	27
74	Cell-free DNA in the plasma of patients with systemic sclerosis. Clinical Rheumatology, 2009, 28, 1437-1440.	2.2	27
75	Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e) Tj ETQq1 1 0.784314 rgBT /Overlock 10	4.2	27
76	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	1.9	27
77	The Concept of Early Systemic Sclerosis Following 2013 ACREULAR Criteria for the Classification of Systemic Sclerosis. Current Rheumatology Reviews, 2014, 10, 38-44.	0.8	26
78	Human Basophil Releasability. VIII. Increased Basophil Releasability in Patients with Scleroderma. Arthritis and Rheumatism, 1991, 34, 1289-1296.	6.7	25
79	Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clinical Rheumatology, 2014, 33, 153-164.	2.2	25
80	Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clinical and Experimental Rheumatology, 2013, 31, 157-65.	0.8	24
81	Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. Health and Quality of Life Outcomes, 2013, 11, 23.	2.4	22
82	Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. Clinical Rheumatology, 2016, 35, 1733-1742.	2.2	22
83	Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. Seminars in Arthritis and Rheumatism, 2014, 43, 673-680.	3.4	21
84	The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. Arthritis Research and Therapy, 2017, 19, 133.	3.5	21
85	Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clinical Rheumatology, 2018, 37, 1239-1247.	2.2	21
86	Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatology International, 2003, 23, 226-230.	3.0	20
87	Classification of systemic sclerosis. Clinics in Dermatology, 1994, 12, 217-223.	1.6	18
88	Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. Clinical Rheumatology, 2003, 22, 393-396.	2.2	18
89	Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin. Autoimmunity Reviews, 2016, 15, 102-109.	5.8	18
90	Evaluation of Cardiac Structures and Function in Systemic Sclerosis by Doppler Echocardiography. Cardiology, 1991, 79, 165-171.	1.4	17

#	Article	IF	Citations
91	Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?. Rheumatology, 2010, 49, 1257-1266.	1.9	16
92	Griseofulvin for eosinophilic fasciitis. Arthritis and Rheumatism, 1980, 23, 1331-1332.	6.7	15
93	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	5.6	15
94	Non-Hodgkinâ€™s lymphoma in systemic sclerosis: case and literature review. Clinical Rheumatology, 2010, 29, 1-6.	2.2	14
95	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. Autoimmunity Reviews, 2020, 19, 102659.	5.8	14
96	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (United States), 2016, 95, e3931.	1.0	13
97	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.9	13
98	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.9	12
99	Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. Patient Related Outcome Measures, 2017, Volume 8, 7-13.	1.2	11
100	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	1.7	11
101	The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clinical Immunology, 2010, 137, 60-73.	3.2	10
102	Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis. PLoS ONE, 2013, 8, e61453.	2.5	10
103	CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously) Tj ETQq1 1 0.784314 rgBT /Overlock	3.6	10
104	Scleroderma Renal Crisis Analysis of Prevalence and Outcome in a Large Italian Series. Journal of Clinical Rheumatology, 1997, 3, 186-193.	0.9	9
105	Apolipoprotein A-I-dependent cholesterol esterification in patients with rheumatoid arthritis. Life Sciences, 2005, 77, 108-120.	4.3	9
106	Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario. Arthritis Research and Therapy, 2009, 11, 103.	3.5	9
107	Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify patients who will evolve. Autoimmunity Reviews, 2019, 18, 102358.	5.8	9
108	NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity. Arthritis Research and Therapy, 2019, 21, 258.	3.5	9

#	Article	IF	Citations
109	Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R72.	3.5	7
110	Serum CXCL4 increase in primary SjÃ¶grenâ€™s syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement. Clinical Rheumatology, 2016, 35, 2591-2596.	2.2	6
111	Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association. PLoS ONE, 2018, 13, e0210023.	2.5	5
112	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. Cardiology Research and Practice, 2019, 2019, 1-7.	1.1	5
113	Hydroxychloroquine significantly reduces serum markers of endothelial injury and NEMO videocapillaroscopy score in systemic sclerosis. Rheumatology, 2019, 58, 1303-1305.	1.9	5
114	HLA-SD antigens in progressive systemic sclerosis. Archives of Dermatological Research, 1979, 266, 213-213.	1.9	4
115	Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. Clinical Rheumatology, 2016, 35, 1985-1991.	2.2	4
116	Lung involvement in â€œestableâ€•undifferentiated connective tissue diseases: a rheumatology perspective. Clinical Rheumatology, 2017, 36, 1833-1837.	2.2	4
117	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts. Medicine (United States), 2018, 97, e0370.	1.0	4
118	Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very earlyâ€“early systemic sclerosis): a TDI study. Clinical and Experimental Medicine, 2018, 18, 237-243.	3.6	4
119	High NEMO score values in nailfold videocapillaroscopy are associated with the subsequent development of ischaemic digital ulcers in patients with systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 237.	3.5	4
120	Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatology International, 2009, 29, 1529-1530.	3.0	3
121	TEMPORAL ARTERY BIOPSY. Lancet, The, 1983, 321, 646.	13.7	2
122	Scleroderma Subsetting. Current Rheumatology Reviews, 2006, 2, 83-87.	0.8	2
123	What does the clinician need to improve patient care in systemic sclerosis?. Annals of the Rheumatic Diseases, 2007, 66, 1129-1131.	0.9	2
124	Preclinical and prognostically relevant cardiovascular disease burden in systemic lupus erythematosus with low clinical damage index. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, e23-e25.	2.6	2
125	Inflammation and Dysmetabolism in Systemic Autoimmune Diseases. Journal of Immunology Research, 2019, 2019, 1-2.	2.2	2
126	The role of aspirin in the primary prevention of accelerated atherosclerosis in systemic autoimmune rheumatic diseases. Rheumatology, 2020, 59, 3593-3602.	1.9	2

#	Article	IF	Citations
127	Comment on: Disease Activity Criteria in Scleroderma. Seminars in Arthritis and Rheumatism, 2008, 37, 271-272.	3.4	1
128	Anti-inflammatory New trends in the treatment of the patient with systemic sclerosis. Expert Opinion on Emerging Drugs, 2008, 13, 227-236.	2.4	1
129	Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 185-189.	1.6	1
130	Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 129-134.	1.6	1
131	The Challenge of Very Early Systemic Sclerosis. Journal of Rheumatology, 2020, 47, 1724-1724.	2.0	1
132	Undifferentiated connective tissue disease at risk for systemic sclerosis: Development of a short-term predictive score and a risk stratification tool. Autoimmunity Reviews, 2021, 20, 102751.	5.8	1
133	Skin Manifestations of Systemic Sclerosis. , 2014, , 191-200.		0
134	Comment on â€˜Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?â€™. Autoimmunity Reviews, 2016, 15, 202.	5.8	0
135	Prevalence of autoantibody patterns in a group of patients with early scleroderma. Rivista Italiana Della Medicina Di Laboratorio, 2018, 14, 25-31.	0.4	0
136	SAT0273â€…PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI). , 2019, , .		0
137	A Scleroderma Patient with Swollen and Tender Joints of Both Hands. , 2011, , 239-250.		0